PD-1 and PD-1 ligands: from discovery to clinical application
The DOI matches its Crossref record; 133 of the 138 references it cites were found in a registry or an index.
Abstract
Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. Because of the wide range of ligand distribution in the body, its biological significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunological privilege. In this review, we would like to summarize the history of PD-1 research since its discovery and recent findings that suggest promising future for the clinical application of PD-1 agonists and antagonists to various human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-1 interacts with an SHP2 tyrosine phosphatase domain, leading to dephosphorylation of signaling molecules downstream of the TCR and inhibiting TCR-mediated activation of IL2 production and T-cell proliferation (13).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Nguyen, L. T., Radhakrishnan, S., Ćirić, B., Tamada, K., Shin, T., Pardoll, D. M., Chen, L., Rodriguez, M., & Pease, L. R. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021466 · Cited by 105 · cited 1×
“However, one group reported that cross-linking of PD-L2 induces stimulatory signal in dendritic cells (DCs), resulting in the augmented antigen presentation ( 26 , 27).”
BackgroundRetractedRadhakrishnan, S., Nguyen, L. T., Ćirić, B., Ure, D., Zhou, B., Tamada, K., Dong, H., Tseng, S.-Y., Shin, T., Pardoll, D. M., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.4.1830 · Cited by 73
RetractedFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Self-citationTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Self-citation
Cited by
Items 201–300 of 1,001
Bowen, A., & Casadevall, A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1504955112 · Cited by 104
Immunogenic anti-cancer chemotherapy as an emerging concept
Haynes, N. M., der Most, R. G. V., Lake, R., & Smyth, M. J. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.008 · Cited by 114
Vandeveer, A. J., Fallon, J. K., Tighe, R., Sabzevari, H., Schlom, J., & Greiner, J. W. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0176 · Cited by 107
“PD-L1 is expressed on a wide variety of human and mouse tumor cells and some immune cell populations, whereas PD-L2 is mainly found on antigen-presenting cells (9, 10).”
BackgroundGut TFH and IgA: key players for regulation of bacterial communities and immune homeostasis
Kato, L. M., Kawamoto, S., Maruya, M., & Fagarasan, S. (2014) · Immunology & Cell Biology · doi:10.1038/icb.2013.54 · Cited by 104
Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
Baraibar, I., Melero, I., Ponz‐Sarvisé, M., & Álvarez, E. C. (2019) · Drug Safety · doi:10.1007/s40264-018-0774-8 · Cited by 112
Vito, C. D., Mikulak, J., Zaghi, E., Pesce, S., Marcenaro, E., & Mavilio, D. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.03.004 · Cited by 120
Zielinski, C. C., Knapp, S., Mascaux, C., & Hirsch, F. R. (2013) · Annals of Oncology · doi:10.1093/annonc/mds647 · Cited by 106
“Despite these similarities, PD-1 and CTLA-4 have distinct ligand specificities and biologic functions; those related to CTLA-4 have been studied more extensively (Figure 2) [54, 55].”
BackgroundKehl, K. L., Yang, S., Awad, M. M., Palmer, N., Kohane, I. S., & Schrag, D. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02321-z · Cited by 104
The GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure
Wu, V. H., Yung, B. S., Faraji, F., Saddawi‐Konefka, R., Wang, Z., Wenzel, A. T., Song, M., Pagadala, M. S., Clubb, L. M., Chiou, J., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01529-7 · Cited by 104
Qi, J., Crinier, A., Escalière, B., Ye, Y., Wang, Z., Zhang, T., Batista, L., Liu, H., Hong, L., Wu, N., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100353 · Cited by 108
Bolandi, N., Derakhshani, A., Hemmat, N., Baghbanzadeh, A., Asadzadeh, Z., Nour, M. A., Brunetti, O., Bernardini, R., Silvestris, N., & Baradaran, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910719 · Cited by 104
“The amino acid sequence homology between PD-L1 and PD-L2 is approximately 40 percent [60,61].”
BackgroundImmune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Tanegashima, T., Togashi, Y., Azuma, K., Kawahara, A., Ideguchi, K., Sugiyama, D., Kinoshita, F., Akiba, J., Kashiwagi, E., Takeuchi, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3991 · Cited by 93
Non-internalising antibody–drug conjugates
Ashman, N., Bargh, J. D., & Spring, D. R. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00446a · Cited by 102
Immunomodulation of mesenchymal stromal cells on regulatory T cells and its possible mechanism
Yan, Z., Zhuansun, Y., Chen, R., Li, J., & Ran, P. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.03.013 · Cited by 99
Dastmalchi, N., Feizi, M. A. H., Khojasteh, S. M. B., Baradaran, B., & Safaralizadeh, R. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118239 · Cited by 95
Messerschmidt, J. L., Prendergast, G. C., & Messerschmidt, G. L. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0282 · Cited by 109
Regulatory T Cells and Human Myeloid Dendritic Cells Promote Tolerance via Programmed Death Ligand-1
Amarnath, S., Costanzo, C. M., Mariotti, J., Ullman, J. L., Telford, W. G., Kapoor, V., Riley, J. L., Levine, B. L., June, C. H., Fong, T., et al. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000302 · Cited by 92
“Such a cell therapy approach may have immediate practical benefit for the treatment of the myriad of diseases that may benefit from PD-1 agonism [52].”
BackgroundPD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression
Mariotti, F. R., Petrini, S., Ingegnere, T., Tumino, N., Besi, F., Scordamaglia, F., Munari, E., Pesce, S., Marcenaro, E., Moretta, A., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1557030 · Cited by 92
Recent developments in the treatment of renal cell carcinoma
Dutcher, J. P. (2013) · Therapeutic Advances in Urology · doi:10.1177/1756287213505672 · Cited by 97
“Another site of immune checkpoint inhibition is at the programmed cell death 1 (PD-1) receptor, which is more selective and has been demonstrated at the tumor cell–T-cell interface [Blank et al. 2004; Okazaki and Honjo, 2007].”
BackgroundPD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
Zhang, J., Yan, Y., Li, J., Adhikari, R., & Fu, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00722 · Cited by 101
“Cancer cells escape immune responses by overexpressing PD-L1 (Figure 1) (Okazaki and Honjo, 2007; Markham, 2016; Cao et al., 2019).”
BackgroundKersten, K., Salvagno, C., & de Visser, K. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00516 · Cited by 89
“CTLA-4 plays a central role in maintaining immune tolerance by competing with CD28 to bind the ligands CD80 and CD86 present on activated APCs to inhibit T cell costimulation.”
BackgroundInfluentialImmune Checkpoint Inhibitor‐Based Strategies for Synergistic Cancer Therapy
He, M., Yang, T., Wang, Y., Wang, M., Chen, X., Ding, D., Zheng, Y., & Chen, H. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002104 · Cited by 96
ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy
Xiao, X., Shi, J., He, C., Bu, X., Sun, Y., Gao, M., Xiang, B., Xiong, W., Dai, P., Mao, Q., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38605-3 · Cited by 101
“As the PD-1 protein contains an extracellular domain, a trans-membrane domain, and a cytoplasmic region 35 , we truncated PD-1 from its cytoplasmic tail and generated the PD-1-Δ C241-288 (deleting amino acid residues from 241 to 288) and Δ C192-288 (missing all cytoplasmic region) mutants,…”
Yang, W., Li, H., Chen, P. W., ALIZADEH, H. M., He, Y.-G., Hogan, R. N., & Niederkorn, J. Y. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2397 · Cited by 92
Sanlorenzo, M., Vujic, I., Posch, C., Dajee, A., Yen, A., Kim, S. T., Ashworth, M. T., Rosenblum, M. D., Algazi, A. P., Osella‐Abate, S., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28555 · Cited by 107
Mo, Z., Liu, J., Zhang, Q., Chen, Z., Mei, J., Liu, L., Yang, S., Li, H., Zhou, L., & You, Z. (2016) · Oncology Letters · doi:10.3892/ol.2016.4744 · Cited by 100
“…the PD-1/PD-L1/PD-L2 immune inhibitory pathway plays a pivotal role in the ability of tumor cells to evade the host's immune system by inhibiting cytotoxic T lymphocyte proliferation, inducing apoptosis of infiltrating T cells, and increasing the amount of regulatory T cells (19,20).”
Li, T., Zhang, C., Zhao, G., Zhang, X., Hao, M., Hassan, S., Zhang, M., Zheng, H., Yang, D., Liu, L., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.036 · Cited by 93
“Programmed cell death 1 (PD-1) is an immune checkpoint that promotes tumor development by driving immune escape via binding to its ligand, programmed cell death-ligand 1 (PDL1) [1,2], which is a T cell co-inhibitory receptor with a structure similar to that of the CTLA-4 immune checkpoint receptor [3].”
BackgroundBridge, J. A., Lee, J., DAUD, A. I., Wells, J. W., & Bluestone, J. A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00351 · Cited by 89
NK cell-based therapeutics for lung cancer
Pockley, A. G., Vaupel, P., & Multhoff, G. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1688298 · Cited by 86
“Allison [5,6], are now revolutionizing the”
Huang, G., Wen, Q., Zhao, Y., Gao, Q., & Bai, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061602 · Cited by 86
“provides a novel and promising approach to manipulate the devastating diseases associated with sepsis [7,20].”
Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications
Uusi-Kerttula, H. K., Hulin-Curtis, S. L., Davies, J. A., & Parker, A. L. (2015) · Viruses · doi:10.3390/v7112923 · Cited by 89
“Antibodies targeting the immune inhibitory co-receptors cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-1 (PD-L1) have demonstrated clinical activity in a variety of tumor types, including melanoma, RCC, and NSCLC [211,212] (reviewed in [213]).”
BackgroundBommarito, D., Hall, C. L., Taams, L. S., & Corrigall, V. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.12949 · Cited by 87
“development of autoimmunity are found in studies showing that polymorphisms in the PDCD1 gene are associated with different human autoimmune diseases, including SLE, type 1 diabetes, RA, psoriasis, ankylosing spondylitis (AS) and MS (218, 219).”
BackgroundGuo, L., Wei, R., Lin, Y., & Kwok, H. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01508 · Cited by 89
Alard, E. L., Butnariu, A.-B., Grillo, M., Kirkham, C., Zinovkin, D. A., Newnham, L. J., Macciochi, J., & Pranjol, M. Z. I. (2020) · Cancers · doi:10.3390/cancers12071826 · Cited by 100
“PD-1, also known as CD279, is a type I transmembrane protein receptor predominantly expressed on T cells, B cells, natural killer (NK) T cells, activated monocytes, and dendritic cells (DCs) [66].”
BackgroundPD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
Filippone, A., Lanza, M., Mannino, D., Raciti, G., Colarossi, C., Sciacca, D., Cuzzocrea, S., & Paterniti, I. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03130-z · Cited by 92
Immune checkpoint inhibitors-induced autoimmunity: The impact of gender
Triggianese, P., Novelli, L., Galdiero, M. R., Chimenti, M. S., Conigliaro, P., Perricone, R., Perricone, C., & Gerli, R. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102590 · Cited by 87
Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT
Tumino, N., Pace, A. L. D., Besi, F., Quatrini, L., Vacca, P., & Moretta, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.638841 · Cited by 90
Hamanishi, J., Mandai, M., Abiko, K., Matsumura, N., Baba, T., Yoshioka, Y., Kosaka, K., & Konishi, I. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.08.013 · Cited by 88
“…factors, such as transforming ( ) [25], IL-10, indoleamine 2,3-dioxygenase (IDO) [26] and cyclooxygenases (COX-1 and COX-2) [27] or upregulating negative regulatory signals, such as programmed cell death-1 (PD-1) ligands (PD-L1, PD-L2) and cytotoxic T lymphocyte antigen-4 (CTLA-4) [28; 29; 30; 31].”
BackgroundThe immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease
Weyand, C. M., Berry, G. J., & Goronzy, J. J. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ma0717-283 · Cited by 92
Bojadzic, D., & Buchwald, P. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180531092503 · Cited by 82
Yu, Y., & Lee, N. Y. (2018) · Future Oncology · doi:10.2217/fon-2018-0405 · Cited by 97
Inhibition of T-cell activity in alopecia areata: recent developments and new directions
Passeron, T., King, B., Sénéschal, J., Steinhoff, M. S., Jabbari, A., Ohyama, M., Tobin, D. J., Randhawa, S., Winkler, A. R., Telliez, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1243556 · Cited by 92
“As PD-1 is thought do downregulate T-cell – mediated immune responses, PD-1 agonism is hypothesized to broadly suppress in fl ammatory diseases including AA (201).”
BackgroundInfluentialPD‐1 suppresses TCR‐CD8 cooperativity during T‐cell antigen recognition
Li, K., Yuan, Z., Lyu, J., Ahn, E., Davis, S. J., Ahmed, R., & Zhu, C. (2021) · Nature Communications · doi:10.1038/s41467-021-22965-9 · Cited by 81
Tembhre, M. K., Parihar, A. S., Sharma, V., Sharma, A., Chattopadhyay, P., & Gupta, S. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13511 · Cited by 84
Ohmura, H., Yamaguchi, T., Hanamura, F., Ito, M., Makiyama, A., Uchino, K., Shimokawa, H., Tamura, S., Esaki, T., Mitsugi, K., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0810-1 · Cited by 81
Chovanec, M., Cierna, Z., Miskovska, V., Machalekova, K., Svetlovska, D., Kalavska, K., Rejlekova, K., Spanik, S., Kajo, K., Babal, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15585 · Cited by 79
“PD-1 is a member of the immunoglobulin superfamily and is expressed on double negative T cells in thymus and on activated CD4+ T cells, CD8+ T cells, natural killer cells, B cells and monocytes [16].”
BackgroundT-Cell Mechanobiology: Force Sensation, Potentiation, and Translation
Harrison, D. L., Fang, Y. H., & Huang, J. (2019) · Frontiers in Physics · doi:10.3389/fphy.2019.00045 · Cited by 89
Brouwer, N. J., Verdijk, R. M., Heegaard, S., Marinkovic, M., Esmaeli, B., & Jager, M. J. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100971 · Cited by 85
“This prevents T cells from targeting the tumour cell (Okazaki and Honjo, 2007) (Fig.”
BackgroundLi, H., Yang, Z., & Guo, Q. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00789-w · Cited by 95
“As a member of the CD28 superfamily [64], PD-1 directly inhibits T-cell activation by binding to its two ligands (PD-L1 and PD-L2) [65, 66], which are widely expressed on the surface of tumor cells and many immune cells [67].”
BackgroundMalaspina, T. S. D. S., Gasparoto, T. H., Nogueira, M. R. S., de Melo, E. J. F., Ikoma, M. R. V., Damante, J. H., Cavassani, K. A., Garlet, G. P., Silva, J. S., & Campanelli, A. P. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1007-5 · Cited by 86
“PD-1 is expressed on the surface of activated T cells, B cells, and macrophages, suggesting that compared to CTLA-4, PD-1 more broadly, negatively regulates immune responses [ 7 ].”
BackgroundState of the art in anti-cancer mAbs
Chiavenna, S. M., Jaworski, J. P., & Vendrell, A. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-016-0311-y · Cited by 82
“Additionally, the fact that the engage of PD-L1 with PD-1 inhibits the proliferation and cytokine production by T cells lymphocytes [104, 105] and that the PD-L1 also expresses on a number of human cancers like urothelial, gastrointestinal, lung, breast, melanoma and ovarian cancer [102, 106–114] prompted to the devel…”
BackgroundLiu, Y., Chongsathidkiet, P., Crawford, B. M., Odion, R., Dechant, C. A., Kemeny, H. R., Cui, X., Maccarini, P. F., Lascola, C. D., Fecci, P. E., et al. (2019) · Immunotherapy · doi:10.2217/imt-2019-0023 · Cited by 77
Ocular Immune Privilege and Ocular Melanoma: Parallel Universes or Immunological Plagiarism?
Niederkorn, J. Y. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00148 · Cited by 86
“…to NK cell-mediated lysis is inversely correlated with the expression of MHC class I molecules (Ma and Niederkorn, 1995; Ma et al., 1995) and is consistent with the “missing self” hypothesis, which posits that NK cells are programmed to kill any cell, malignant or non-malignant, that fails to…”
BackgroundResultDrakes, M. L., Mehrotra, S., Aldulescu, M., Potkul, R. K., Liu, Y., Grisoli, A., Joyce, C., O’Brien, T. E., Stack, M. S., & Stiff, P. J. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0414-z · Cited by 88
PD-1 regulation in immune homeostasis and immunotherapy
Gao, M., Shi, J., Xiao, X., Yao, Y., Chen, X., Wang, B., & Zhang, J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216726 · Cited by 92
Fukasawa, T., Yoshizaki, A., Ebata, S., Nakamura, K., Saigusa, R., Miura, S., Yamashita, T., Hirabayashi, M., Ichimura, Y., Taniguchi, T., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40164 · Cited by 78
“Programmed death 1 (PD-1), a member of the CD28/B7 family of costimulatory molecules, is a type I transmembrane glycoprotein that regulates T cell tolerance (8,9).”
BackgroundTackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy
Lodewijk, I., Nunes, S. P., Henrique, R., Jerónimo, C., Dueñas, M., & Paramio, J. M. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01046-0 · Cited by 78
“Treatment of leukemia cells with decitabine (DAC) translated into upregulation of PD-L1, PD-L2, PD-1 and CTLA-4 in these cells [151].”
BackgroundParakh, S., Ernst, M., & Poh, A. R. (2021) · Cancers · doi:10.3390/cancers13246228 · Cited by 80
Du, Y., Liang, X., Li, Y., Sun, T., Xue, H., Jin, Z., & Tian, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.11.019 · Cited by 75
“PD-L1, a 290-amino acid type I transmembrane glycoprotein, engages programmed death-1 (PD-1) to suppress T-cell activi ty and restrict tumor cell killing [1, 2].”
Backgrounddu Rusquec, P., de Calbiac, O., Robert, M., Campone, M., & Frenel, J. (2019) · Cancer Management and Research · doi:10.2147/cmar.s151023 · Cited by 83
“Death Ligand 1 (PD-L1) and 2 (PD-L2), are expressed on tumor cells, macrophages, and dendritic cells.(3) The binding of PD1 with PD-L1 triggers the tolerance of tumor cells by the immune system, promoting tumor growth.”
Sui, X., Ma, J., Han, W., Wang, X., Fang, Y., Li, D., Pan, H., & Zhang, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5107 · Cited by 82
“PD-1, a member of the immunoglobulin (Ig) superfamily, contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) as well as an immunoreceptor tyrosine switch motif (ITSM) in its cytoplasmic tail and delivers inhibitory signals to immune cells upon the binding of its ligand, PD-L1 or PD-L2 [23].”
BackgroundPembrolizumab-induced myasthenia gravis: A fatal case report
March, K. L., Samarin, M. J., Sodhi, A., & Owens, R. E. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155216687389 · Cited by 73
Xing, Y., Mi, C., Wang, Z., Zhang, Z. H., Li, M. Y., Zuo, H. X., Wang, J. Y., Jin, X., & Ma, J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.004 · Cited by 78
Lanuza, P. M., Pesini, C., Arias, M. A., Calvo, C., Ramírez-Labrada, A., & Pardo, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03010 · Cited by 75
Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations
Madariaga, A., Lheureux, S., & Oza, A. M. (2019) · Cancers · doi:10.3390/cancers11030416 · Cited by 83
“PD1 and its receptor PD-L1 play an important role in the interaction of tumour cells and tumour-specific T cells [180]; antibodies against these immune checkpoints can activate the anti-tumour response.”
BackgroundMoorman, J. P., Zhang, C. L., Ni, L., Cheng, J., Zhang, Y., Wu, X. Y., Thayer, P., Islam, T. M., Borthwick, T., & Yao, Z. Q. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.02.052 · Cited by 71
Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma
Ingels, A., Campi, R., Capitanio, U., Amparore, D., Bertolo, R. G., Carbonara, U., Erdem, S., Kara, Ö., Klatte, T., KRIEGMAIR, M. C., et al. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00592-3 · Cited by 82
Targeted Covalent Modification Strategies for Drugging the Undruggable Targets
Tamura, T., Kawano, M., & Hamachi, I. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00745 · Cited by 81
Imai, Y., Ayithan, N., Wu, X., Yuan, Y., Wang, L. L., & Hwang, S. T. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500448 · Cited by 70
“Of note, PD-L1, but not PD-L2, was upregulated on IMQ-treated keratinocytes (Fig.”
BackgroundInfluentialKudo, M. (2019) · Liver Cancer · doi:10.1159/000503254 · Cited by 70
Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis
Wang, C., Zhu, H., Zhou, Y., Mao, F., Lin, Y., Pan, B., Zhang, X., Xu, Q., Huang, X., & Sun, Q. (2017) · The Breast Journal · doi:10.1111/tbj.12753 · Cited by 71
Zuo, H. X., Jin, Y., Wang, Z., Li, M. Y., Zhang, Z. H., Wang, J. Y., Xing, Y., Ri, M., Jin, C. H., Xu, G. H., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112835 · Cited by 74
Pathogenic roles of B lymphocytes in systemic sclerosis
Yoshizaki, A. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.01.002 · Cited by 79
Rewriting History: Epigenetic Reprogramming of CD8+ T Cell Differentiation to Enhance Immunotherapy
Zebley, C. C., Gottschalk, S., & Youngblood, B. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.008 · Cited by 69
Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update
Kudo, M. (2016) · Liver Cancer · doi:10.1159/000449342 · Cited by 70
Aguirre, L. E., Guzman, M. E., Lopes, G., & Hurley, J. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0195 · Cited by 68
“PD1 binds namely to three ligands on the surface of immune mediators: PD-L1, PD-L2, and B7 [12, 14].”
BackgroundThe panoply of αβT cells in the skin
Nomura, T., Kabashima, K., & Miyachi, Y. (2014) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2014.07.010 · Cited by 68
Eso, Y., & Seno, H. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820948773 · Cited by 72
Okiyama, N., & Katz, S. I. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.06.005 · Cited by 70
“Programmed cell death 1 (PD-1) expressed on T cells is an immunoreceptor that negatively regulates antigen receptor signaling upon interacting with either of two ligands, PD-L1 and PD-L2 (PD-Ls) [1].”
Mkrtichyan, M., Chong, N., Abu Eid, R., Wallecha, A., Singh, R., Rothman, J., & Khleif, S. N. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-15 · Cited by 68
“The expression of PD-L2 on various tumor cells was also demonstrated [16,17].”
BackgroundWang, S., Li, H., Li, B., Xie, T., Zhu, T., Sun, L., Ren, H., & Ye, Z. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.05.016 · Cited by 70
Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges
Nimmagadda, S. (2020) · Cancers · doi:10.3390/cancers12113173 · Cited by 69
“PD-1 plays important roles in regulating T cell activation, tolerance, and exhaustion, and effector T cell responses [4].”
BackgroundKim, S., Lee, M., Song, Y., Lee, S., Choi, I., Park, I.-S., Kim, J., Kim, J., Kim, K. M., & Seo, H. R. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01912-y · Cited by 73
Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma
Ahn, H., Yang, J. M., Kim, H., Chung, J.-H., Ahn, S., Jeong, W., & Paik, J. H. (2017) · Oncotarget · doi:10.18632/oncotarget.19842 · Cited by 66
“Programmed cell death ligand-1 (PD-L1) is a cell-surface glycoprotein that induces T cell anergy and apoptosis by activating the PD-1 receptors on T lymphocytes [5].”
BackgroundZhang, N., Tu, J., Wang, X., & Chu, Q. (2019) · Immunotherapy · doi:10.2217/imt-2018-0110 · Cited by 69
MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy
Jiang, X., Dudzinski, S. O., Beckermann, K. E., Young, K. L., McKinley, E. T., McIntyre, J. O., Rathmell, J. C., Xu, J., & Gore, J. C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000328 · Cited by 70
Immune Checkpoint Molecules—Inherited Variations as Markers for Cancer Risk
Wagner, M., Jasek, M., & Karabon, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.606721 · Cited by 80
Wang, Q., Li, G., Ma, X., Liu, L., Liu, J., Yin, Y., Li, H., Chen, Y., Zhang, X., Zhang, L., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05609-2 · Cited by 68
“PD-L1 and its receptor, programmed cell death 1 (PD-1), can downregulate T-cell activity and maintain immune tolerance to self-antigens [3, 4].”
BackgroundStructures of PD-1 with its ligands: Sideways and dancing cheek to cheek
Freeman, G. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805459105 · Cited by 72
Checkpoint Inhibition in Myeloma: Opportunities and Challenges
Costa, F., Das, R., Bailur, J. K., Dhodapkar, K. M., & Dhodapkar, M. V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02204 · Cited by 70
“High PD-L1 expression is associated with a poor prognosis in solid tumors, including lung, ovarian or colon cancer, thus supporting the impressive results that PD-1/PD-L1 blockade has led in several cancers (36).”
BackgroundResultSong, M., Liang, J., Wang, L., Li, W., Jiang, S., Xu, S., Tang, L., Du, Q., Liu, G., Meng, H., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110757 · Cited by 74
Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD‐L1 in Cancer Therapy
Wang, Y., Zhou, Y., Yang, L., Lei, L., He, B., Cao, J., & Gao, H. (2023) · Advanced Science · doi:10.1002/advs.202303175 · Cited by 86
Wang, L., Qian, J., Lu, Y., Li, H., Bao, H., He, D., Liu, Z., Zheng, Y., He, J., Li, Y., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.071340 · Cited by 73
“B7-H1 induces an inhibitory signal to T-cell-mediated immunity, plays an important role in T-cell regulation of various immune responses, and is involved in peripheral tolerance, autoimmunity and infection.(12) Recent studies demonstrated that the expression of B7H1 protein is aberrantly up-regulated in various cancer…”
BackgroundThe effects of PDL-Ig on collagen-induced arthritis
Wang, G., Hu, P., Yang, J. L., Shen, G., & Wu, X. (2009) · Rheumatology International · doi:10.1007/s00296-009-1249-0 · Cited by 68
“PD-L2 is inducibly expressed on dendritic cells and macrophages, whereas PD-L1 is broadly expressed on both professional and nonprofessional APCs as well as a wide variety of nonhematopoietic cell types [4].”
BackgroundRen, X., Wu, H., Lu, J., Zhang, Y., Luo, Y., Xu, Q., Shen, S., & Liang, Z. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1423919 · Cited by 64
“PD1 itself was reported to be expressed in activated T cells.(30) Therefore, it is possible that PD1 may act through a TIL-mediated anti-tumor inflammatory response rather than in tumor immune evasion.”
BackgroundHuang, L., Wang, R., Xie, K., Zhang, J., Tao, F., Pi, C., Feng, Y., Gu, H., & Fang, J. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06384-4 · Cited by 67
Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions
Lamas, N. J., Martel, A., Nahon‐Estève, S., Goffinet, S., Macocco, A., Bertolotto, C., Lassalle, S., & Hofman, P. M. (2021) · Cancers · doi:10.3390/cancers14010096 · Cited by 72
“Programmed cell death receptor-1 (PD-1), one of the best studied and most advanced immune checkpoint inhibition targets, is expressed in lymphocytes (T and B cells), macrophages and natural killer cells and their effector function is halted when it binds its co-ligands programmed cell death-ligand 1 (PD-L1) and progra…”
BackgroundMartini, D. J., Hamieh, L., McKay, R. R., Harshman, L. C., Moreira, R. B., Norton, C. K., Steinharter, J. A., Krajewski, K. M., Gao, X. Y., Schutz, F. A., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0220 · Cited by 64
Xie, M., Huang, X., Ye, X., & Qian, W. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105999 · Cited by 69
LSD1 silencing contributes to enhanced efficacy of anti-CD47/PD-L1 immunotherapy in cervical cancer
Xu, S., Wang, X., Yang, Y., Li, Y., & Wu, S. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03556-4 · Cited by 64
Metadata
- Authors
- Okazaki, T., & Honjo, T.
- Affiliations
- Kyoto University (JP)
- ORCID
- Okazaki, T.
- Venue
- International Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-06-22
- Volume
- 19
- Issue
- 7
- Pages
- 813-824
- ISSN
- 0953-8178 (ISSN-L)
- 1460-2377
- OpenAlex
- W2122639773
- Cited by
- 1,310
- References
- 138
- Citations by year
- 2026: 26 · 2025: 53 · 2024: 96 · 2023: 94 · 2022: 100 · 2021: 125 · 2020: 152 · 2019: 101 · 2018: 100 · 2017: 112 · 2016: 72 · 2015: 70 · 2014: 41 · 2013: 48 · 2012: 29
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Biomedical Innovation
- Japan Society for the Promotion of Science (17047024, 19689012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, PD-L1, PD-L2, immune checkpoint, SHP2, autoimmunity, antitumor immunity, transplantation immunity, allergy, immune privilege, clinical application
- MeSH terms
- Animals, Autoimmune Diseases, Humans, Immunity, Ligands, Antigens, CD, Intercellular Signaling Peptides and Proteins, Mice, B7-H1 Antigen, Programmed Cell Death 1 Ligand 2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.